Kauf mal einen Franzosen !!
Seite 1 von 6 Neuester Beitrag: 25.04.21 02:01 | ||||
| Eröffnet am: | 09.03.10 21:40 | von: Biggemann | Anzahl Beiträge: | 148 |
| Neuester Beitrag: | 25.04.21 02:01 | von: Petralrcya | Leser gesamt: | 39.844 |
| Forum: | Hot-Stocks | Leser heute: | 3 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 | 4 | 5 | 6 6 > | ||||
EDAP TMS' 30th Anniversary EDAP TMS "30th Anniversary
In 2009, EDAP TMS celebrates 30 years of success in developing and marketing minimally invasive therapies using innovative technologies. Im Jahr 2009 feiert EDAP TMS 30 Jahre Erfolg in der Entwicklung und Vermarktung von minimal-invasiven Therapien mit innovativen Technologien. EDAP TMS, has built a strong global reputation of "excellence and leadership in therapeutic ultrasound". EDAP TMS, hat eine starke globale Ruf der "Exzellenz und Führung in der therapeutischen Ultraschall gebaut.
At the same time, EDAP TMS has always been at the forefront for customer service, offering a wide portfolio of devices and a full range of services to all types of medical institutions. Zur gleichen Zeit hat EDAP TMS immer an vorderster Front für die Kundenbetreuung wurde, bietet eine breite Palette von Geräten und eine breite Palette von Dienstleistungen für alle Arten von medizinischen Einrichtungen.
Consequently, EDAP TMS has maintained a solid faithful customer base that is constantly growing and securing the durability of the Company and its products portfolio with the recent 7th generation of Sonolith® lithotriptors and the 3rd generation of Ablatherm® HIFU for prostate cancer. Folglich hat EDAP TMS Gläubigen eine solide Kundenbasis, die ständig wächst und die Sicherung der Nachhaltigkeit der Unternehmen und die Produkte-Portfolio mit den bisherigen 7. Generation von Sonolith ® Lithotripter und die 3. Generation von Ablatherm ® HIFU für Prostatakrebs erhalten.
For 30 years, EDAP TMS has been demonstrating its capacity to build high standard long-term partnerships that every prospect is looking for. Seit 30 Jahren hat EDAP TMS wurde demonstriert seine Fähigkeit, hohen Standard zu bauen langfristige Partnerschaften, die alle Aussicht sucht.
Centres & Treatments worldwide
12.02.2015 18:02
The HECAM(1) project is a €41 million research and development competitiveness project, financed to the tune of €18.2 million as part of the future investments program(2). Its ambition is to develop detection, diagnosis and treatment tools for hepatocellular carcinoma (HCC), in other words primary liver cancer.
Originally an idea of Claire Corot (Guerbet’s Research & Innovation and Business Development Licensing Director and member of the board of directors of Medicen), the HCC multi-technological approach project was structured by GE Healthcare. Piloted by GE Healthcare, HECAM comprises Guerbet, seven SMEs(3) and three academic partners(4). They provide and develop first-rate scientific and technical competencies within the project.
The benefit of a collaborative approach for a disease with major health consequences such as HCC is huge. And France has excellent academic, structured research, particularly in the field of medical imaging, paving the way for the emergence of innovative solutions.
Click here to read the press release (only in french).
(1) HEpatocellular CArcinoma Multi-technological.
(2) The program is piloted by the French General Investment Commission (CGI) and operated by Bpifrance. Bpifrance, a subsidiary of the Caisse des Dépôts et de l’État, provides loans, guarantees and capital to companies, from their startup to flotation on the stock market.
(3) BioPredictive, CarThera and IntegraGen (Greater Paris Region), BioSIMS Technologies (Upper Normandy), Intrasense (Languedoc-Roussillon), EDAP TMS France and Fluoptics (Rhône-Alpes).
(4) Gustave Roussy, Europe’s leading cancer treatment center, the Paris Public Hospitals Group (with four hospitals: Beaujon, Jean Verdier, Henri Mondor and Paul Brousse) and the French Healthcare and Medical Research Institute (five INSERM units). The consortium is also supported by the Montpellier Regional University Hospital.
http://www.guerbet.com/our-group/news/2015/news/.../intervention.html
Rekordumsatz im Jahr 2014 von 26,8 Mio. EUR (35,4 Mio. USD); 11% Wachstum gegenüber dem Vorjahr;
Gesamtjahr HIFU Umsatz stieg 70% gegenüber 2013;
Starke Cash-Position von 12,1 Mio. EUR (14,7 Mio. USD) zum 31. Dezember 2014;
Filing Direkt De-novo-Petition für Ablatherm HIFU pro FDA Diskussionen.
http://www.nasdaq.com/press-release/...ar-2014-results-20150401-01011
"The publication reports a 100% cancer specific survival at 5 years, a 94% rate of continence preservation and 80% rate of potency preservation."